ATE414511T1 - Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung - Google Patents

Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung

Info

Publication number
ATE414511T1
ATE414511T1 AT01989170T AT01989170T ATE414511T1 AT E414511 T1 ATE414511 T1 AT E414511T1 AT 01989170 T AT01989170 T AT 01989170T AT 01989170 T AT01989170 T AT 01989170T AT E414511 T1 ATE414511 T1 AT E414511T1
Authority
AT
Austria
Prior art keywords
fenretinide
retinide
pharmaceutical compositions
solvent
increased bioavailability
Prior art date
Application number
AT01989170T
Other languages
English (en)
Inventor
Shanker Gupta
Barry Maurer
C Reynolds
B Vishnuvajjala
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Application granted granted Critical
Publication of ATE414511T1 publication Critical patent/ATE414511T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01989170T 2000-12-05 2001-12-05 Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung ATE414511T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25146300P 2000-12-05 2000-12-05

Publications (1)

Publication Number Publication Date
ATE414511T1 true ATE414511T1 (de) 2008-12-15

Family

ID=22952077

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01989170T ATE414511T1 (de) 2000-12-05 2001-12-05 Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung

Country Status (8)

Country Link
US (1) US7169819B2 (de)
EP (1) EP1349545B1 (de)
JP (2) JP4384409B2 (de)
AT (1) ATE414511T1 (de)
DE (1) DE60136648D1 (de)
DK (1) DK1349545T3 (de)
ES (1) ES2316489T3 (de)
WO (1) WO2002058689A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1594544T (pt) * 2003-01-31 2016-07-14 Los Angeles Childrens Hospital Composições orais de fenretinida tendo biodisponibilidade aumentada e métodos de utilização das mesmas
ITMI20032019A1 (it) * 2003-10-17 2005-04-18 Fidia Farmaceutici Microemulsioni di retinoidi e composizioni farmaceutiche che le contengono
BRPI0405798B8 (pt) * 2003-11-28 2021-05-25 Halex Istar Ind Farmaceutica L processo de eliminação de resíduos alcalinos presentes no 9-((1,3-dihidroxipropan-2-iloxi)metil)-2-amino-1h-purin-6(9h)-ona e apresentação farmacêutica
KR100862930B1 (ko) 2004-06-23 2008-10-13 시리온 테라퓨틱스, 인크. 레티닐 유도체를 사용하여 안 증상을 치료하기 위한 방법및 조성물
WO2006047475A2 (en) * 2004-10-25 2006-05-04 Sytera, Inc. Detection and analysis of ophthalmically-relevant fluorescent molecules
AU2005304822B2 (en) * 2004-11-04 2008-10-16 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
WO2007115134A2 (en) 2006-03-29 2007-10-11 Wayne State University Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
US7321064B1 (en) * 2007-03-08 2008-01-22 Cedarburg Pharmaceuticals, Inc. Preparation of amides of retinoic acid via mixed anhydride and mixed carbonate intermediates
WO2009045345A1 (en) * 2007-09-28 2009-04-09 Childrens Hospital Los Angeles Research Institute Metabolic degradation inhibitors for anti-hyperproliferative agents
US8063020B2 (en) * 2007-12-22 2011-11-22 Simpkins Cuthbert O Resuscitation fluid
US8906855B2 (en) * 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US8618056B2 (en) * 2007-12-22 2013-12-31 Cuthbert O. Simpkins Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
ES2525337T3 (es) 2008-02-21 2014-12-22 The Royal Institution For The Advancement Of Learning/Mcgill University Tratamiento de enfermedades o estados neurales
US8088822B2 (en) * 2008-07-08 2012-01-03 Ji Zhang Use of fenretinide or bioactive derivatives thereof and pharmaceutical compositions comprising the same
EP2174650A1 (de) * 2008-10-08 2010-04-14 Polichem SA Modifizierte Freisetzungsemulsionen zur Anwendung auf der Haut und der Vaginalschleimhaut
CA2817198C (en) * 2009-11-12 2018-05-01 Texas Tech University Compositions and methods for treating hyperproliferative disorders
WO2012068169A2 (en) * 2010-11-15 2012-05-24 Texas Tech University Substance for increasing the production of a specific acyl-chain dihydroceramide(s) for improving the effectiveness of cancer treatments
BR112013011942A2 (pt) * 2010-11-15 2016-11-01 Univ Michigan formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
US10406127B2 (en) 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
ES3009527T3 (en) 2014-07-25 2025-03-27 Laurent Pharmaceuticals Solid oral formulation of fenretinide
KR102547925B1 (ko) * 2014-09-17 2023-06-26 폰다지오네 이르씨스 이스티튜토 나찌오날레 데이 투모리 암 치료를 위한 치료제로서의 4-옥소-n-(4-히드록시페닐)레틴아미드 유도체
WO2022170398A1 (en) * 2021-02-11 2022-08-18 Monash University Formulations for improved bioavailability of fenretinide

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190594A (en) 1975-11-03 1980-02-26 Johnson & Johnson Retinoic acid derivatives
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
DE3432696A1 (de) * 1984-09-03 1986-03-13 Siemens AG, 1000 Berlin und 8000 München Antriebsvorrichtung fuer einen leistungsschalter mit exzenter und richtgesperre
US4665098A (en) * 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4960799A (en) 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
DE69109297T2 (de) * 1990-08-13 1995-11-09 David W. Byfield Mass. Yesair Gemischte lipid-bicarbonat-kolloidale partikel zur abgabe von arzneien und kalorien.
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
EP0671953A4 (de) 1992-11-13 1996-01-10 Univ Ohio State Res Found C-glycosid-analoge des n-(hydroxyphenyl)retinamid-o-glucuronids.
US5464870A (en) 1993-02-10 1995-11-07 Ortho Pharmaceutical Corporation Methods of inhibiting development of leukoplakia with fenretinide
EP0619116A3 (en) * 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
DE69614855T2 (de) * 1995-06-06 2002-03-28 Biomolecular Products, Inc. Gemischte lipid-bicarbonat kolloidale partikel zur abgabe von arzneistoffen oder kalorien
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
BE1011216A3 (fr) 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
EP1091745B1 (de) * 1998-06-29 2008-10-01 Children's Hospital Of Los Angeles Behandlung hyperproliferativer erkrankungen
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
AU2002211776A1 (en) * 2000-10-17 2002-04-29 Board Of Regents, The University Of Texas System A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes

Also Published As

Publication number Publication date
US7169819B2 (en) 2007-01-30
US20020183394A1 (en) 2002-12-05
JP4384409B2 (ja) 2009-12-16
DK1349545T3 (da) 2009-02-16
EP1349545A1 (de) 2003-10-08
EP1349545A4 (de) 2006-05-24
WO2002058689A1 (en) 2002-08-01
JP2005510447A (ja) 2005-04-21
DE60136648D1 (de) 2009-01-02
EP1349545B1 (de) 2008-11-19
ES2316489T3 (es) 2009-04-16
JP2009292834A (ja) 2009-12-17

Similar Documents

Publication Publication Date Title
DE60136648D1 (de) Pharmazeutische zusammensetzungen von fenretinid mit erhöhter bioverfügbarkeit und verfahren zu deren verwendung
Kawakami et al. Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents
Godwin et al. Influence of drug lipophilicity on terpenes as transdermal penetration enhancers
EA200601588A1 (ru) Стабилизированные перенасыщенные твёрдые растворы липофильных лекарственных средств
Alvarez-Nunez et al. Relationship between Polysorbate 80 solubilization descriptors and octanol–water partition coefficients of drugs
BR0214679A (pt) Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
EA200601460A1 (ru) Препарат микроэмульсии с высокой концентрацией пропофола для анестезирующих применений
MXPA05013278A (es) Composiciones farmaceuticas que comprenden compuestos activos de vitamina d.
ATE153532T1 (de) Zusammensetzungen, die einen fluorokohlenwasserstoff und eine lipophile/fluorophile organische verbindung enthalten und ihre verwendungen
AU775158B2 (en) Water-miscible pharmaceutical compositions of paclitaxel
FI970995A0 (fi) Farmaseuttisia yhdisteitä
CA2194226A1 (en) Stable Oil-In-Water Emulsions Incorporating a Taxine (Taxol) and Method of Making Same
DE60217367D1 (de) Nanopartikelzusammensetzungen enthaltend insulin
CA2716576A1 (en) Fulvestrant formulations
ES2145158T3 (es) Nueva formulacion de emulsion.
Mukherjee et al. Development and oral bioavailability assessment of a supersaturated self-microemulsifying drug delivery system (SMEDDS) of albendazole
DE60119082D1 (de) Anästhetikum enthaltende formulierungen
SE0000774D0 (sv) New formulation
EA200401625A1 (ru) Стабилизированные фармацевтические композиции на основе полиоксиэтилированного касторового масла и способ их получения
Alkrad et al. Development and characterization of microemulsions containing hyaluronic acid
Wang et al. Acacetin-loaded microemulsion for transdermal delivery: preparation, optimization and evaluation
DE60000223D1 (de) O/W-Emulsion enthaltende Fibern und ihre Verwendung in der Kosmetik
ATE516016T1 (de) Selbstemulgierende formulierungen von cetp- hemmern
AP1754A (en) Pharmaceutical compositions based on azetidine derivatives.
Jain et al. Solubilization of NSC-639829

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties